Abbonarsi

Propensity score methods to control for confounding in observational cohort studies: a statistical primer and application to endoscopy research - 19/08/19

Doi : 10.1016/j.gie.2019.04.236 
Jeff Y. Yang, BA, BS 1, Michael Webster-Clark, PharmD 1, Jennifer L. Lund, PhD 1, Robert S. Sandler, MD, MPH 1, 2, Evan S. Dellon, MD, MPH 2, Til Stürmer, MD, PhD 1,
1 Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina, Chapel Hill, North Carolina, USA 
2 Center for Gastrointestinal Biology and Disease, School of Medicine, University of North Carolina, Chapel Hill, North Carolina, USA 

Reprint requests: Til Stürmer, MD, PhD, Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina, 2105B McGavran-Greenberg Hall, CB #7435, Chapel Hill, NC 27599.Department of EpidemiologyGillings School of Global Public HealthUniversity of North Carolina2105B McGavran-Greenberg HallCB #7435Chapel HillNC27599

Abstract

Background and Aims

Confounding is a major concern in nonexperimental studies of endoscopic interventions and can lead to biased estimates of the effects of treatment. Propensity score methods, which are commonly used in the pharmacoepidemiology literature, can effectively control for baseline confounding by balancing measured baseline confounders and risk factors and creating comparable populations of treated and untreated patients.

Methods

We propose the following 5-step checklist to guide the use and evaluation of propensity score methods: (1) select covariates, (2) assess “Table 1” balance in risk factors before propensity score implementation, (3) estimate and implement the propensity score in the study cohort, (4) reassess “Table 1” balance in risk factors after propensity score implementation, and (5) critically evaluate differences between matched and unmatched patients after propensity score implementation. We then applied this checklist to an endoscopy example using a study cohort of 411 adults with newly diagnosed eosinophilic esophagitis (EoE), some of whom were treated with esophageal dilation.

Results

We identified 156 patients, aged 18 and older, who were treated with esophageal dilation, and 255 patients who were nondilated. We successfully matched 148 (95%) dilated patients to nondilated patients who had a propensity score within 0.1, based on patient age, sex, race, self-reported food allergy, and presence of narrowing at baseline endoscopy. Crude imbalances were observed before propensity score matching in several baseline covariates, including age, sex, and narrowing; however, propensity score matching was successful in achieving balance across all measured covariates.

Conclusions

We provide an introduction to propensity score methods, including a straightforward checklist for implementing propensity score methods in nonexperimental studies of treatment effectiveness. Moreover, we demonstrate the advantage of using “Table 1” as a simple but effective diagnostic tool for evaluating the success of propensity score methods in an applied example of esophageal dilation in EoE.

Il testo completo di questo articolo è disponibile in PDF.

Abbreviations : EoE, SMD


Mappa


 DISCLOSURE: The following authors received research support for this study from the National Institutes of Health (grant nos. R01 AG056479 and T32 DK 007634): J. Y. Yang, J. L. Lund, and T. Stürmer. In addition, the following author disclosed financial relationships relevant to this publication: T. Stürmer: Salary support recipient as Director of Comparative Effectiveness Research, NC TraCS Institute, UNC Clinical and Translational Science Award (UL1TR002489), the Center for Pharmacoepidemiology (current members: GlaxoSmithKline, UCB BioSciences, Merck, Shire), from pharmaceutical companies (GSK, Amgen, AstraZeneca, Novo Nordisk), and from a generous contribution from Dr. Nancy A. Dreyer to the Department of Epidemiology, University of North Carolina at Chapel Hill; stock owner in Novartis, Roche, BASF, AstraZeneca, and Novo Nordisk. All other authors disclosed no financial relationships relevant to this publication.


© 2019  American Society for Gastrointestinal Endoscopy. Pubblicato da Elsevier Masson SAS. Tutti i diritti riservati.
Aggiungere alla mia biblioteca Togliere dalla mia biblioteca Stampare
Esportazione

    Citazioni Export

  • File

  • Contenuto

Vol 90 - N° 3

P. 360-369 - settembre 2019 Ritorno al numero
Articolo precedente Articolo precedente
  • ASGE guideline on screening and surveillance of Barrett’s esophagus
  • ASGE STANDARDS OF PRACTICE COMMITTEE, Bashar Qumseya, Shahnaz Sultan, Paul Bain, Laith Jamil, Brian Jacobson, Sharmila Anandasabapathy, Deepak Agrawal, James L. Buxbaum, Douglas S. Fishman, Suryakanth R. Gurudu, Terry L. Jue, Sapna Kripalani, Jeffrey K. Lee, Mouen A. Khashab, Mariam Naveed, Nirav C. Thosani, Julie Yang, John DeWitt, Sachin Wani, ASGE Standards of Practice Committee Chair
| Articolo seguente Articolo seguente
  • Endoscopic GERD therapy: a primer for the transoral incisionless fundoplication procedure
  • Fateh Bazerbachi, Kumar Krishnan, Barham K. Abu Dayyeh

Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.

Già abbonato a @@106933@@ rivista ?

@@150455@@ Voir plus

Il mio account


Dichiarazione CNIL

EM-CONSULTE.COM è registrato presso la CNIL, dichiarazione n. 1286925.

Ai sensi della legge n. 78-17 del 6 gennaio 1978 sull'informatica, sui file e sulle libertà, Lei puo' esercitare i diritti di opposizione (art.26 della legge), di accesso (art.34 a 38 Legge), e di rettifica (art.36 della legge) per i dati che La riguardano. Lei puo' cosi chiedere che siano rettificati, compeltati, chiariti, aggiornati o cancellati i suoi dati personali inesati, incompleti, equivoci, obsoleti o la cui raccolta o di uso o di conservazione sono vietati.
Le informazioni relative ai visitatori del nostro sito, compresa la loro identità, sono confidenziali.
Il responsabile del sito si impegna sull'onore a rispettare le condizioni legali di confidenzialità applicabili in Francia e a non divulgare tali informazioni a terzi.


Tutto il contenuto di questo sito: Copyright © 2026 Elsevier, i suoi licenziatari e contributori. Tutti i diritti sono riservati. Inclusi diritti per estrazione di testo e di dati, addestramento dell’intelligenza artificiale, e tecnologie simili. Per tutto il contenuto ‘open access’ sono applicati i termini della licenza Creative Commons.